Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Yuichi Sakamori"'
Autor:
Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Chronic obstructive pulmonary disease (COPD) may coexist with lung cancer, but the impact on prognosis is uncertain. Moreover, it is unclear whether pharmacological treatment for COPD improves the patient’s prognosis. We retrospectively in
Externí odkaz:
https://doaj.org/article/f3c791af74a046499c35180097eeba07
Autor:
Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, Kentaro Ueno, Young Hak Kim, Shigeo Muro, Toyohiro Hirai
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/54a067459b054ee180ce6a077620ee5a
Autor:
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting b
Externí odkaz:
https://doaj.org/article/3f80ddddea7640be87705e31f5e46a2a
Autor:
Ichiro Yamauchi, Akihiro Yasoda, Shigemi Matsumoto, Yuichi Sakamori, Young Hak Kim, Motoo Nomura, Atsushi Otsuka, Toshinari Yamasaki, Ryoichi Saito, Morimasa Kitamura, Toshio Kitawaki, Masakatsu Hishizawa, Nobuko Kawaguchi-Sakita, Toshihito Fujii, Daisuke Taura, Masakatsu Sone, Nobuya Inagaki
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216954 (2019)
BackgroundBlocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs). Clinical features of a thyroid irAE including its predictability and relationship to prognosis remain to be eluci
Externí odkaz:
https://doaj.org/article/5af6610dbdcb437fa513957cc5348edd
Autor:
Takahiro Tsuji, Young Hak Kim, Hiroaki Ozasa, Yuichi Sakamori, Hiroki Nagai, Hitomi Ajimizu, Yoshitaka Yagi, Atsuyuki Furukawa, Hironori Haga, Michiaki Mishima
Publikováno v:
Respiratory Medicine Case Reports, Vol 15, Iss C, Pp 48-50 (2015)
Introduction: Pulmonary spindle cell carcinoma (SpCC) is a rare subtype of non-small-cell lung cancer (NSCLC) and, in general, is chemoresistance. Case: A sixty-five year-old male patient with metastatic pulmonary SpCC was initially treated with cisp
Externí odkaz:
https://doaj.org/article/072e36e2b7f54ce7a275f59bb9829aa0
Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
Publikováno v:
Case Reports in Oncology, Vol 6, Iss 2, Pp 430-433 (2013)
We report the case of a 50-year-old male former smoker. He was diagnosed as having lung adenocarcinoma and treated with induction chemoradiation therapy followed by surgery and adjuvant chemotherapy. Molecular testing revealed that his tumor had an e
Externí odkaz:
https://doaj.org/article/c5ea3e10daac4a3ebf2a033169b87290
Autor:
Katsuhiro Masago, Yosuke Togashi, Masahide Fukudo, Tomohiro Terada, Kaoru Irisa, Yuichi Sakamori, Shiro Fujita, Young Hak Kim, Tadashi Mio, Ken-ichi Inui, Michiaki Mishima
Publikováno v:
Case Reports in Oncology, Vol 3, Iss 2, Pp 98-105 (2010)
Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R
Externí odkaz:
https://doaj.org/article/93bb0a58010443c3b5e6f25cbd0aae69
Autor:
Akiko Fukuhara, Katsuhiro Masago, Masashi Neo, Shunsuke Fujibayashi, Shiro Fujita, Yukimasa Hatachi, Kaoru Irisa, Yuichi Sakamori, Yosuke Togashi, Young Hak Kim, Tadashi Mio, Michiaki Mishima
Publikováno v:
Case Reports in Oncology, Vol 3, Iss 1, Pp 63-71 (2010)
Background: Spinal metastases of patients with advanced stage lung cancer are an important target for palliative therapy, because their incidence is high, and they often cause severe symptoms and worsen the quality of life. Surgery is one of the most
Externí odkaz:
https://doaj.org/article/640d54b5531946c29560dc0c927695fd
Autor:
Kazuhito Ueki, Yukinori Matsuo, Noriko Kishi, Masahiro Yoneyama, Hironori Yoshida, Yuichi Sakamori, Hiroaki Ozasa, Toyohiro Hirai, Takashi Mizowaki
Publikováno v:
Journal of Radiation Research. 63:636-645
Prophylactic cranial irradiation (PCI) is recommended for patients with limited-stage small-cell lung cancer (LS-SCLC) who respond well to initial treatment. However, PCI is often omitted because of its potential neurotoxicity in the era of modern di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145e8fc8c13c3c51116d3fd9f74bb2ea
https://doi.org/10.1093/jrr/rrac035
https://doi.org/10.1093/jrr/rrac035
Autor:
Young Hak Kim, Toyohiro Hirai, Mitsuyoshi Ueda, Yuichi Sakamori, Hiroki Nagai, Yoshitaka Yagi, Hironori Yoshida, Koichi Hasegawa, Kiyoshi Uemasu, Takashi Nomizo, Yuto Yasuda, Ryoko Okutani, Hitomi Ajimizu, Yasushi Yoshimura, Koh Furugaki, Tomoko Funazo, Shunsuke Aburaya, Wataru Aoki, Hiroaki Ozasa, Takahiro Tsuji
Fig. S1. Supplementary data for Fig. 1 Fig. S2. Supplementary drug sensitivity data to ALK inhibitors in KTOR1 and KTOR1-RE. Fig. S3. Supplementary results of the phosphoproteome analysis Fig. S4. Saracatinib sensitized KTOR1-RE cells to crizotinib F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f8b92c4e090d208d1fd9cf32555131
https://doi.org/10.1158/1541-7786.22515762
https://doi.org/10.1158/1541-7786.22515762
